# Progress Note 01 — Initial plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Leonard Nimoy (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML017-SYN-TD
- Date: 2014-02-10
- Fictional facility: St. Posthumous Health Center
- Fictional author: Carla Benedetti, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

## Subjective

The patient participates in this fictional visit for new patient visit for COPD and breathlessness walking any distance. **S**

## Objective

FEV1 before bronchodilator: 1.18 L (low); FEV1 after bronchodilator: 1.26 L (low); FEV1 percent predicted after bronchodilator: 46% (low); FVC after bronchodilator: 2.93 L; FEV1/FVC after bronchodilator: 0.43 (low); Blood eosinophil count: 0.18 10*3/uL; Alpha-1 antitrypsin: 138 mg/dL; Hemoglobin: 14.6 g/dL; Creatinine: 0.98 mg/dL; PHQ-9: 3. All results are synthetic.

BP 132/78 mmHg; pulse 84 bpm; respirations 20/min; temperature 36.7 °C; oxygen saturation 93% on room air; weight 80 kg; BMI 23.4 kg/m². All vital signs are synthetic.

## Assessment

Active problems: Chronic obstructive pulmonary disease, GOLD 3 (severe airflow limitation), group B, confirmed on spirometry; synthetic modern classification linked to his publicly disclosed COPD; Former smoker, quit about 30 years ago through a cessation program. Strengths and supports remain part of the care plan. **S**

## Medication changes

- Continued without change: Albuterol 90 mcg/actuation inhaler, two inhalations as needed for breathlessness (prescribed by his previous clinician; used once or twice most days before intake) **S**
- Started: Tiotropium-olodaterol 2.5/2.5 mcg soft mist inhaler, two inhalations once daily **S**

## Plan

- Start tiotropium-olodaterol 2.5/2.5 mcg soft mist inhaler, two inhalations each morning, keep albuterol as needed, and teach and check inhaler technique at every visit; no inhaled corticosteroid while there are no exacerbations and blood eosinophils are below 300 per microliter. Guideline: Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, 2025 report (2025); CMID: Clinical Monitoring Intelligence Database, chronic obstructive pulmonary disease monograph (2026) **S**
- Pulmonology consultation to confirm the GOLD grade and group, review the inhaler choice and the place of an inhaled corticosteroid, assess oxygen need at rest and on exertion, interpret the alpha-1 antitrypsin result, and advise on pulmonary rehabilitation and lung cancer screening. Guideline: Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, 2025 report (2025); CMID: Clinical Monitoring Intelligence Database, chronic obstructive pulmonary disease monograph (2026) **S**
- At every visit: CAT, mMRC, exacerbations in the past 12 months, GOLD group, pulse oximetry, smoking status, BMI, and inhaler technique. Spirometry at diagnosis and at least yearly; alpha-1 antitrypsin once; blood eosinophils at baseline and before any change in inhaled corticosteroid; arterial blood gas only if resting saturation is 92 percent or less; long-term oxygen only for resting saturation of 88 percent or less confirmed twice at least three weeks apart; ECG and cardiovascular risk at baseline. Guideline: Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, 2025 report (2025); CMID: Clinical Monitoring Intelligence Database, chronic obstructive pulmonary disease monograph (2026); Home Oxygen Therapy for Adults with Chronic Lung Disease: An Official American Thoracic Society Clinical Practice Guideline (2020) **S**
- Written COPD action plan: what an exacerbation looks like (more breathlessness, more or discolored sputum), when to use extra albuterol, and when to call the clinic the same day or go to emergency care. Guideline: Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, 2025 report (2025); CMID: Clinical Monitoring Intelligence Database, chronic obstructive pulmonary disease monograph (2026) **S**
- Lung cancer screening reviewed and not offered: he quit smoking more than 15 years ago, so he does not meet the USPSTF criteria despite more than 20 pack-years. Guideline: CMID: Clinical Monitoring Intelligence Database, chronic obstructive pulmonary disease monograph (2026); Lung Cancer: Screening (2021) **S**
- Vaccines for COPD: yearly influenza (high dose at 65 and older), PCV20 once, RSV once at 75 and older, COVID-19 by CDC guidance, Tdap every ten years, and recombinant zoster. Guideline: CMID: Clinical Monitoring Intelligence Database, chronic obstructive pulmonary disease monograph (2026); Adult Immunization Schedule by Age (2026) **S**
- Comorbidity and mood screening at intake and yearly (depression, anxiety, cardiovascular disease, osteoporosis, reflux, sleep, nutrition), and advance care planning at the wellness visit. Guideline: Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, 2025 report (2025); CMID: Clinical Monitoring Intelligence Database, chronic obstructive pulmonary disease monograph (2026) **S**
